Oral leukoplakia (OL) is the most common premalignancy in the oral cavity. A small proportion of OLs progresses to oral squamous cell carcinoma (OSCC). To assess OSCC risk of OLs, we investigated the role of the transcriptional repressor, Enhancer of Zeste Homolog 2 (EZH2), in oral tumorigenesis and its clinical implication as an OSCC risk predictor. Immunohistochemistry was used to measure EZH2 expression in OLs from 76 patients including 37 who later developed OSCC and 39 who did not. EZH2 expression was associated with clinicopathologic parameters and clinical outcomes. To determine the biological role of EZH2 in OL, EZH2 level was reduced using EZH2-siRNAs in Leuk-1 cells, its impact on cell cycle, anchorage dependent/independent growth, and invasion was assessed. We observed strong EZH2 expression in 34 (45%), moderate expression in 26 (34%), and weak/no expression in 16 (21%) of the OLs. The higher EZH2 levels were strongly associated with dysplasia (P<0.001) and OSCC development (P<0.0001). Multivariate analysis indicated that EZH2 expression was the only independent factor for OSCC development (P<.0001). At 5 years after diagnosis, 80% of patients whose OLs expressed strong EZH2 developed OSCC whereas only 24% patients with moderate and none with weak/no EZH2 expression did so (P<0.0001). In Leuk-1 cells, EZH2 down-regulation resulted in G1 arrest; decreased invasion capability, decreased anchorage independent growth; down-regulation of cyclin D1 and up-regulation of p15
INTRODUCTION:
Oral Leukoplakia (OL) represents the most common oral precancerous condition (1) . It is a clinical term to describe lesions that present as a white patch and cannot be characterized clinically or histologically as any other disease. Histologically, OL has a wide spectrum, ranges from simple hyperkeratosis to severe dysplasia or carcinoma in situ. Each clinical appearance or phase of OL has different transformation potential ranging from 1% to 47% in different studies (2) . Malignant transformation often occurs several years after the onset of the white plaques but it can also occur within just few months or in decades (3, 4) .
The prediction of OL's malignant potential is unreliable in current clinical practice.
The histopathological grading of dysplasia is still the most contemporary method to assess the malignant potential in patients with OL, yet this method is subjective and the clinical decisions based on the method are not satisfactory (5, 6) . Considering the high morbidity and mortality associated with OSCC, the major challenges are to identify OLs with higher risk for OSCC development independent of dysplastic changes and to reveal molecular targets which may be regulated to prevent OSCC development (7, 9).
Development of OSCC is evolutionary and characterized by multistep carcinogenic processes, in which activation of oncogenes and inactivation of tumor suppressor genes are the key features leading to clonal expansion and malignant transformation of normal oral epithelial cells (9) (10) (11) . Enhancer of Zeste Homolog 2 (EZH2) is the catalytic subunit of Polycomb repressive complex 2 (PRC2), a highly conserved histone methyltransferase that methylates lysine-27 of histone H3 (H3-K27) (12) . H3-K27 methylation is commonly associated with DNA methylation and silencing of genes responsible for differentiation in organisms ranging from plants to mammals including humans (12, 13) . It has been shown that EZH2 is involved in methylation and silencing of a subset of genes implicated in cell differentiation, suggesting that it may play a key role in cell differentiation and maintenance of adult stem cell populations (14, 15) . Furthermore, overexpression of EZH2 has been observed in several human cancer types including oral cancers, suggesting that EZH2 is an oncogene and plays a role in oral tumorigenesis (16) (17) (18) .
In this study, we tested the hypothesis that EZH2 activation is critical in malignant transformation of oral epithelial cells, and therefore may serve as an indicator to predict OSCC risk in patients with OLs.
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PATIENTS AND METHODS

Patients and Specimens
Patients
One of the tissue sections from each patient was stained with Hematoxylin and Eosin (H&E) and examined to verify histopathology diagnosis before further analysis.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue, were cut into 4 µm tissue sections. Mayer's hematoxylin (Sigma-Aldrich corp. St Louis, Mo). The EZH2 labeling index (LI) was defined semi-quantitatively as the intensity of staining (0, 1, 2, 3), multiplied by the percentage of positive epithelial thickness (25%, 50%, 75%) and given the scores: weak, moderate and strong, for the quartiles of the EZH2 LI: ≤75, 100 and ≥150 -≤ 225, respectively, as the weighted mean of cells displaying nuclear immunoreactivity.
19
For comparison, the samples were also analyzed using the Aperio ScanScope and Image Scope software, Nuclear v9 algorithm, with quartiles ≤75, >75 -<150, and ≥150, as weak, moderate and strong, respectively.
Cell culture
OL cell line (Leuk-1) (20) was cultured in keratinocyte serum-free (KSF) medium with 25μg/mL bovine pituitary extract (BPE) and 0.2 ng/ml recombinant epidermal growth factor (EGF) (Invitrogen).
SiRNA knockdown
Two anti-EZH2 siRNA, each targets the two splice variants of EZH2, and FAM labeled negative control siRNA, were purchased from (Ambion Inc). The anti-EZH2 siRNA sequences were 5'-GCUGACCAUUGGGACAGUATT-3' for (siRNA-4916) and 5'- 
Cell proliferation assay
Viability of Leuk-1 cells transfected with EZH2 siRNA was measured every 24 h for 6 days using the Cell Proliferation Reagent WST-1 (Roche Diagnostics Corporation).
The experiment was independently repeated 3 times.
Anchorage-independent growth assay
24 h after EZH2 siRNA transfection, cells in 0.35% agarose with KSF, EGF and BPE medium were plated on top of solidified 0.5% agarose in 6-well plate in triplicates.
The gels were covered with 1 ml medium and and incubated for 3 weeks with medium change every 3~4 days. Colonies >0.1 mm in diameter were counted under a microscopic field at 40x magnification. Means of colonies were calculated based on numbers from triplicate wells for each treatment condition. In vitro cell invasion assay BD BioCoat Matrigel invasion chambers (BD Biosciences) were used. EZH2 siRNA transfected leuk-1 cells were seeded in the upper chamber in KSF media without rEGF and BPE, while KSF media with rEGF and BPE was placed in the lower chamber.
After 20 hours incubation, cells on the lower surface of the membrane were fixed in 4% paraformaldehyde and stained with 0.5% crystal violet. Cells in at least 6 random microscopic fields 100x were counted. The experiment was performed in duplicates and repeated 3 times.
Statistical analysis
Event free survival (EFS) or "OSCC free survival" was the outcome variable. The independent variable EZH2 expression status and its interaction with histology were 
RESULTS
Patients with OL
The study cohort consisted of 76 OL patients who had no prior cancer history from a single hospital. Among these patients, 37(49%) developed OSCC after the initial OL diagnosis, with median follow up time of 2 years, whereas 39 (51%) remained OSCC free with a median follow-up time of 11.4 years. The general characteristics of the patient population are presented in (Table 1 and supplementary Table) .
EZH2 expression and clinicopathological parameters
EZH2 expression was mainly observed as nuclear while cytoplasmic staining was observed in some cases. The intensity of EZH2 expression in the OLs ranged from negative to strongly positive and the extent of EZH2 expression varied from being limited only to the basal cell layer to being observed in full thickness of the epithelium (Fig. 1A) .
Among the OL lesions, 34 (45%) showed strong EZH2 staining, 26 (34%) showed moderate EZH2 staining, and 16 (21%) showed no or weak EZH2 staining (Table 1) . EZH2 staining levels were strongly associated with the grade of dysplasia (P < .001) (Fig. 1A and Table 1 ). However, the expression of EZH2 was independent of dysplasia. (Table 1 and supplment Fig. 1 ).
EZH2 expression and OSCC development
To determine the role of EZH2 expression in OSCC development, we analyzed OSCC-Free survival probability which was defined as years from time of diagnosis of OL to time of diagnosis of OSCC, based on EZH2 expression in OLs. We found that EZH2 expression was strongly associated with OSCC-Free survival in an expression level dependent manner (P < .0001 by Log-Rank test; Fig. 1B ). At 5-years, none of the 16 patients whose lesions showed no or weak EZH2 expression developed OSCC, whereas 6 (24%) of the moderate, and 28 (80%) of the strong EZH2 expressing OLs developed OSCC. Consistent with this, digital image analysis (Supplement Fig. 2 ), showed only 1 out of 15 lesions with weak EZH2 expression developed OSCC after 5 years of OL diagnosis (Supplement table 1). In the univariate analysis, we analyzed the association between the potential risk factors including EZH2 expression and OSCC development at 3-years and 5-years after OL diagnosis. EZH2 expression and OL histology were significantly associated with OSCC development (P <0.0001 and P <0.01, respectively; Table 2 ). Interestingly, alcohol use showed a borderline association with a reduced OSCC risk (P = 0.05). We then performed a multivariate analysis to include EZH2 expression, OL histology and alcohol use as co-factors. In this analysis (N=53), we found that EZH2 expression was the only independent factor significantly associated with OSCC development (P < 0.0001) ( Table 3) .
EZH2 and malignant features in OL cells
To explore the underlying mechanism by which EZH2 contribute to malignant transformation of OL cells, we used EZH2-siRNAs (si-4916 and si-4917) to specifically down-regulate EZH2 expression levels in an OL cell line, Leuk-1. At 72 h after EZH2-siRNA treatment, Leuk-1 cells showed reduced EZH2 levels and proliferation. The cells also showed an increased fraction of G1 phase (G1 arrest) with the decreased EZH2 level, in comparison to the cells treated with scrambled siRNA (Fig. 2A) 
identify molecular mechanisms underlying the G1 cell cycle arrest by EZH2 downregulation, we measured a panel of key proteins involved in G1 phase regulation. At 48 hours after EZH2-siRNA treatment, levels of cyclin D1 (CCND1) were significantly reduced while on the other hand, p15 INK4B levels were increased (Fig. 2B) , CDK4, and CDK6 expression levels (Fig.   2B ). This data suggests that EZH2 may play a role in early oral tumorigenesis by promoting cell cycle progression through modulating p15 (Fig. 3A) . We then analyzed the effect of EZH2 down-regulation in anchorage-independent growth using soft agar colony formation assay. Leuk-1 cells treated with EZH2-siRNAs showed significantly reduced capability to form colonies in soft agar (Fig. 3B) . Because CCND1 has been linked to malignant progression of oral premalignancy (21, 22), we investigated the possibility that EZH2 may promote invasion of Leuk-1 cells through modulating the expression of CCND1. EZH2-siRNA treated cells exhibited a significantly reduced invasion capability measured by a modified Boyden chamber invasion assay (Fig. 3C) .
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DISCUSSION
A molecular-based model for OSCC development has been proposed in literature, which include deregulation of cell cycle proteins (23). CCND1 is one of the proteins that is frequently upregulated in oral premalignancies leading to malignant transformation and an increased risk of OSCC development (21, 22). Although CCND1 gene may be amplified in oral tumorigenesis, overexpression of CCND1 is also observed in OLs and OSCCs without the gene amplification (21). It has been reported that high EZH2 expression is associated with up-regulation of CCND1 in gastric cancer whereas the pharmacological inhibition of EZH2 leads to down-regulation of CCND1 levels in skin cancer (24, 25). Our observation that EZH2 down-regulation resulted in a decreased CCND1 expression level in OL cells is consistent with the previous reports and suggests that EZH2 is involved in CCND1 regulation in oral tumorigenesis.
In OLs and OSCC, p15
INK4B
promoter hypermethlation is frequently observed (26, 27) . EZH2 may mediate this process through H3K27 trimethylation and recruitment of DNA methyltransferases (15, 28, 29) . Consistent with this mechanism, we found increased p15 Importantly, despite the difference, the general conclusion in this study did not change. 
